Active Immunotherapy of Cancer

References

• Alpen B, Gure AO, Scanlan MJ, et al. (2002). A new member of the NY-ESO-1 gene family is ubiquitously expressed in somatic tissues and evolutionarily conserved. Gene, 297, 141–9
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, et al. (2015). Talimogene laherparepvec improves durable response rate in patients with advanced melanoma. J Clin Oncol, 33, 2780–8. doi:10.1200/JCO.2014.58.3377
   PubMed Web of Science ®Google Scholar
• Aubert RD, Kamphorst AO, Sarkar S, et al. (2011). Antigen-specific CD4 T-cell help rescues exhausted CD8 T cells during chronic viral infection. Proc Natl Acad Sci U S A, 108, 21182–7
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Peterson AC, et al. (2004). PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res, 64, 1140–5
   PubMed Web of Science ®Google Scholar
• Boon T, van der Bruggen P. (1996). Human tumor antigens recognized by T lymphocytes. J Exp Med, 183, 725–9
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Drake CG, Wollner I, et al. (2010). Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 28, 3167–75
   PubMed Web of Science ®Google Scholar
• Brichard V, Van Pel A, Wolfel T, et al. (1993). The tyrosinase gene codes for an antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med, 178, 489–95
   PubMed Web of Science ®Google Scholar
• Carey TE, Takahashi T, Resnick LA, et al. (1976). Cell surface antigens of human malignant melanoma: Mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells. Proc Natl Acad Sci U S A, 73, 3278–82
   PubMed Web of Science ®Google Scholar
• Castle JC, Kreiter S, Diekmann J, et al. (2012). Exploiting the mutanome for tumor vaccination. Cancer Res, 72, 1081–91
   PubMed Web of Science ®Google Scholar
• Cheever MA, Disis ML, Bernhard H, et al. (1995). Immunity to oncogenic proteins. Immunol Rev, 145, 33–59
   PubMed Web of Science ®Google Scholar
• Chen YT, Scanlan MJ, Sahin U, et al. (1997). A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening. Proc Natl Acad Sci U S A, 94, 1914–18
   PubMed Web of Science ®Google Scholar
• Chodon T, Comin-Anduix B, Chmielowski B, et al. (2014). Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res, 20, 2457–65
   PubMed Web of Science ®Google Scholar
• Clemente CG, Mihm MC, Jr Bufalino R, et al. (1996). Prognostic value of tumor infiltrating lymphocytes in the vertical growth phase of primary cutaneous melanoma. Cancer, 77, 1303–10
   PubMed Web of Science ®Google Scholar
• Coley WB. (1991). The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893. Clin Orthop, 262, 3–11
   Google Scholar
• Coulie PG, Brichard V, Van Pel A, et al. (1994). A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas. J Exp Med, 180, 35–42
   PubMed Web of Science ®Google Scholar
• Davila ML, Riviere I, Wang X, et al. (2014). Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med, 6, 224ra25
   PubMed Web of Science ®Google Scholar
• Davis ID, Chen W, Jackson H, et al. (2004). Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans. Proc Natl Acad Sci U S A, 101, 10697–702
   PubMed Web of Science ®Google Scholar
• Dillman RO, McClay EF, Barth NM, et al. (2015). Dendritic versus tumor cell presentation of autologous tumor antigens for active specific immunotherapy in metastatic melanoma: Impact on long-term survival by extent of disease at the time of treatment. Cancer Biother Radiopharm, 30, 187–94
   PubMedGoogle Scholar
• Doll R, Kinlen L. (1970). Immunosurveillance and cancer: Epidemiological evidence. Br Med J, 4, 420–2
   PubMed Web of Science ®Google Scholar
• Dong H, Strome SE, Salomao DR, et al. (2002). Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion. Nat Med, 8, 793–800
   PubMed Web of Science ®Google Scholar
• Duan F, Duitama J, Al Seesi S, et al. (2014). Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity. J Exp Med, 211, 2231–48
   PubMed Web of Science ®Google Scholar
• Dudley ME, Gross CA, Somerville RP, et al. (2013). Randomized selection design trial evaluating CD8+-enriched versus unselected tumor-infiltrating lymphocytes for adoptive cell therapy for patients with melanoma. J Clin Oncol, 31, 2152–9
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF, et al. (2002). Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science, 298, 850–4
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Shelton TE, et al. (2003). Generation of tumor-infiltrating lymphocyte cultures for use in adoptive transfer therapy for melanoma patients. J Immunother, 26, 332–42
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Yang JC, et al. (2005). Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma. J Clin Oncol, 23, 2346–57
   PubMed Web of Science ®Google Scholar
• Dudley ME, Yang JC, Sherry R, et al. (2008). Adoptive cell therapy for patients with metastatic melanoma: Evaluation of intensive myeloablative chemoradiation preparative regimens. J Clin Oncol, 26, 5233–9
   PubMed Web of Science ®Google Scholar
• Dunn GP, Bruce AT, Ikeda H, et al. (2002). Cancer immunoediting: From immunosurveillance to tumor escape. Nat Immunol, 3, 991–8
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. (2004a). The immunobiology of cancer immunosurveillance and immunoediting. Immunity, 21, 137–48
   PubMed Web of Science ®Google Scholar
• Dunn GP, Old LJ, Schreiber RD. (2004b). The three Es of cancer immunoediting. Annu Rev Immunol, 22, 329–60
   PubMed Web of Science ®Google Scholar
• Funada Y, Noguchi T, Kikuchi R, et al. (2003). Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer. Oncol Rep, 10, 309–13
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Senovilla L, Vacchelli E, et al. (2012). Trial watch: Dendritic cell-based interventions for cancer therapy. Oncoimmunology, 1, 1111–34
   PubMed Web of Science ®Google Scholar
• Galon J, Angell HK, Bedognetti D, Marincola, FM. (2013). The continuum of cancer immunosurveillance: Prognostic, predictive, and mechanistic signatures. Immunity, 39, 11–26
   PubMed Web of Science ®Google Scholar
• Gattinoni L, Lugli E, Ji Y, et al. (2011). A human memory T cell subset with stem cell-like properties. Nat Med, 17, 1290–7
   PubMed Web of Science ®Google Scholar
• Gerlinger M, Rowan AJ, Horswell S, et al. (2012). Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med, 366, 883–92
   PubMed Web of Science ®Google Scholar
• Gil M, Komorowski MP, Seshadri M, et al. (2014). CXCL12/CXCR4 blockade by oncolytic virotherapy inhibits ovarian cancer growth by decreasing immunosuppression and targeting cancer-initiating cells. J Immunol, 193, 5327–37
   PubMed Web of Science ®Google Scholar
• Gnjatic S, Cai Z, Viguier M, et al. (1998). Accumulation of the p53 protein allows recognition by human CTL of a wild-type p53 epitope presented by breast carcinomas and melanomas. J Immunol, 160, 328–33
   PubMed Web of Science ®Google Scholar
• Gubin MM, Zhang X, Schuster H, et al. (2014). Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens. Nature, 515, 577–81
   PubMed Web of Science ®Google Scholar
• Guidoboni M, Gafa R, Viel A, et al. (2001). Microsatellite instability and high content of activated cytotoxic lymphocytes identify colon cancer patients with a favorable prognosis. Am J Pathol, 159, 297–304
   PubMed Web of Science ®Google Scholar
• Hartveit F. (1998). Breast cancer: Poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: A preliminary report. Oncol Rep, 5, 423–6
   PubMed Web of Science ®Google Scholar
• Huang RY, Eppolito C, Lele S, et al. (2015). LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model”. Oncotarget (Epub ahead of print, July 23, 2015)
   Google Scholar
• Hunder NN, Wallen H, Cao J, et al. (2008). Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med, 358, 2698–703
   PubMed Web of Science ®Google Scholar
• Hwang WT, Adams SF, Tahirovic E, et al. (2012). Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis. Gynecol Oncol, 124, 192–8
   PubMed Web of Science ®Google Scholar
• Iwai Y, Ishida M, Tanaka Y, et al. (2002). Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci U S A, 99, 12293–7
   PubMed Web of Science ®Google Scholar
• Jager E, Jager D, Knuth A. (1999). CTL-defined cancer vaccines: Perspectives for active immunotherapeutic interventions in minimal residual disease. Cancer Metastasis Rev, 18, 143–50
   PubMed Web of Science ®Google Scholar
• Kalos M, Levine BL, Porter DL, et al. (2011). T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med, 3, 95ra73
   PubMed Web of Science ®Google Scholar
• Kantoff PW, Higano CS, Shore ND, et al. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411–22
   PubMed Web of Science ®Google Scholar
• Karlsson M, Marits P, Dahl K, et al. (2010). Pilot study of sentinel-node-based adoptive immunotherapy in advanced colorectal cancer. Ann Surg Oncol, 17, 1747–57
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Jennings C, et al. (1995). Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol, 154, 3961–8
   PubMed Web of Science ®Google Scholar
• Kelleher RJ, Balu-Iyer S, Loyall JL, et al. (2015). Extracellular vesicles present in human ovarian tumor microenvironments induce a phosphatidylserine dependent arrest in the T cell signaling cascade. Cancer Immunol Res (Epub ahead of print, June 25, 2015). doi:10.1158/2326-6066.CIR-15-0086
   Google Scholar
• Knuth A, Danowski B, Oettgen HF, Old LJ. (1984). T-cell-mediated cytotoxicity against autologous malignant melanoma: Analysis with interleukin 2-dependent T-cell cultures. Proc Natl Acad Sci U S A, 81, 3511–15
   PubMed Web of Science ®Google Scholar
• Koya RC, Mok S, Comin-Anduix B, et al. (2010). Kinetic phases of distribution and tumor targeting by T cell receptor engineered lymphocytes inducing robust antitumor responses. Proc Natl Acad Sci U S A, 107, 14286–91
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, et al. (2015a). Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med, 373, 23–34
   PubMed Web of Science ®Google Scholar
• Larkin J, Lao CD, Urba WJ, et al. (2015b). Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials. JAMA Oncol, 1, 433–40
   PubMed Web of Science ®Google Scholar
• Lee DW, Kochenderfer JN, Stetler-Stevenson M, et al. (2015). T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet, 385, 517–28
   PubMed Web of Science ®Google Scholar
• Lennette ET, Winberg G, Yadav M, et al. (1995). Antibodies to LMP2A/2B in EBV-carrying malignancies. Eur J Cancer, 31A, 1875–8
   PubMed Web of Science ®Google Scholar
• Lethe B, Lucas S, Michaux L, et al. (1998). LAGE-1, a new gene with tumor specificity. Int J Cancer, 76, 903–8
   PubMed Web of Science ®Google Scholar
• Linnemann C, van Buuren MM, Bies L, et al. (2015). High-throughput epitope discovery reveals frequent recognition of neo-antigens by CD4+ T cells in human melanoma. Nat Med, 21, 81–5
   PubMed Web of Science ®Google Scholar
• Lu YC, Yao X, Crystal JS, et al. (2014). Efficient identification of mutated cancer antigens recognized by T cells associated with durable tumor regressions. Clin Cancer Res, 20, 3401–10
   PubMed Web of Science ®Google Scholar
• MacKie RM, Reid R, Junor B. (2003). Fatal melanoma transferred in a donated kidney 16 years after melanoma surgery. N Engl J Med, 348, 567–8
   PubMed Web of Science ®Google Scholar
• Mandruzzato S, Brasseur F, Andry G, et al. (1997). A CASP-8 mutation recognized by cytolytic T lymphocytes on a human head and neck carcinoma. J Exp Med, 186, 785–93
   PubMed Web of Science ®Google Scholar
• Marincola FM, Jaffee EM, Hicklin DJ, Ferrone S. (2000). Escape of human solid tumors from T-cell recognition: Molecular mechanisms and functional significance. Adv Immunol, 74, 181–273
   PubMedGoogle Scholar
• Matloubian M, Concepcion RJ, Ahmed R. (1994). CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection. J Virol, 68, 8056–63
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, et al. (2010). Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A, 107, 7875–80
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Tsuji T, Luescher I, et al. (2014). Nonclassical antigen-processing pathways are required for MHC class II-restricted direct tumor recognition by NY-ESO-1-specific CD4(+) T cells. Cancer Immunol Res, 2, 341–50
   Google Scholar
• Maude SL, Frey N, Shaw PA, et al. (2014). Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med, 371, 1507–17
   PubMed Web of Science ®Google Scholar
• Melief CJ, van der Burg SH. (2008). Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines. Nat Rev Cancer, 8, 351–60
   PubMed Web of Science ®Google Scholar
• Mikucki ME, Fisher DT, Matsuzaki J, et al. (2015). Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun, 6, 7458
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR, et al. (2006). Cancer regression in patients after transfer of genetically engineered lymphocytes. Science, 314, 126–9
   PubMed Web of Science ®Google Scholar
• Naito Y, Saito K, Shiiba K, et al. (1998). CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer. Cancer Res, 58, 3491–4
   PubMed Web of Science ®Google Scholar
• Nauts HC, McLaren JR. (1990). Coley toxins—the first century. Adv Exp Med Biol, 267, 483–500
   PubMedGoogle Scholar
• Odunsi K, Matsuzaki J, Karbach J, et al. (2012). Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients. Proc Natl Acad Sci U S A, 109, 5797–802
   PubMed Web of Science ®Google Scholar
• Odunsi K, Qian F, Matsuzaki J, et al. (2007). Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A, 104, 12837–42
   PubMed Web of Science ®Google Scholar
• Old LJ. (2001). Cancer/testis (CT) antigens—a new link between gametogenesis and cancer. Cancer Immun, 1, 1
   PubMedGoogle Scholar
• Old LJ. (2008). Cancer vaccines: An overview. Cancer Immun, 8 (Suppl. 1), 1
   PubMedGoogle Scholar
• Qiao J, Kottke T, Willmon C, et al. (2008a). Purging metastases in lymphoid organs using a combination of antigen-nonspecific adoptive T cell therapy, oncolytic virotherapy and immunotherapy. Nat Med, 14, 37–44
   PubMed Web of Science ®Google Scholar
• Qiao J, Wang H, Kottke T, et al. (2008b). Loading of oncolytic vesicular stomatitis virus onto antigen-specific T cells enhances the efficacy of adoptive T-cell therapy of tumors. Gene Ther, 15, 604–16
   PubMed Web of Science ®Google Scholar
• Rizvi NA, Hellmann MD, Snyder A, et al. (2015). Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science, 348, 124–8
   PubMed Web of Science ®Google Scholar
• Robbins PF, El-Gamil M, Li YF, et al. (1996). A mutated beta-catenin gene encodes a melanoma-specific antigen recognized by tumor infiltrating lymphocytes. J Exp Med, 183, 1185–92
   PubMed Web of Science ®Google Scholar
• Robbins PF, Morgan RA, Feldman SA, et al. (2011). Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol, 29, 917–24
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP, Yang JC, et al. (2008). Adoptive cell transfer: A clinical path to effective cancer immunotherapy. Nat Rev Cancer, 8, 299–308
   PubMed Web of Science ®Google Scholar
• Sahin U, Tureci O, Schmitt H, et al. (1995). Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci U S A, 92, 11810–13
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A, 102, 18538–43
   PubMed Web of Science ®Google Scholar
• Savina A, Jancic C, Hugues S, et al. (2006). NOX2 controls phagosomal pH to regulate antigen processing during crosspresentation by dendritic cells. Cell, 126, 205–18
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Altorki NK, Gure AO, et al. (2000). Expression of cancer-testis antigens in lung cancer: Definition of bromodomain testis-specific gene (BRDT) as a new CT gene, CT9. Cancer Lett, 150, 155–64
   PubMed Web of Science ®Google Scholar
• Scanlan MJ, Chen YT, Williamson B, et al. (1998). Characterization of human colon cancer antigens recognized by autologous antibodies. Int J Cancer, 76, 652–8
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, Toes RE, van der Voort EI, et al. (1998). T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature, 393, 480–3
   PubMed Web of Science ®Google Scholar
• Schumacher K, Haensch W, Roefzaad C, Schlag PM. (2001). Prognostic significance of activated CD8(+) T cell infiltrations within esophageal carcinomas. Cancer Res, 61, 3932–6
   PubMed Web of Science ®Google Scholar
• Senovilla L, Vacchelli E, Garcia P, et al. (2013). Trial watch: DNA vaccines for cancer therapy. Oncoimmunology, 2, e23803
   PubMed Web of Science ®Google Scholar
• Shankaran V, Ikeda H, Bruce AT, et al. (2001). IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature, 410, 1107–11
   PubMed Web of Science ®Google Scholar
• Simpson AJ, Caballero OL, Jungbluth A, et al. (2005). Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer, 5, 615–25
   PubMed Web of Science ®Google Scholar
• Slaney CY, Rautela J, Parker BS. (2013). The emerging role of immunosurveillance in dictating metastatic spread in breast cancer. Cancer Res, 73, 5852–7
   PubMed Web of Science ®Google Scholar
• Snyder A, Makarov V, Merghoub T, et al. (2014). Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med, 371, 2189–99
   PubMed Web of Science ®Google Scholar
• Street SE, Hayakawa Y, Zhan Y, et al. (2004). Innate immune surveillance of spontaneous B cell lymphomas by natural killer cells and gammadelta T cells. J Exp Med, 199, 879–84
   PubMed Web of Science ®Google Scholar
• Tindle RW. (1996). Human papillomavirus vaccines for cervical cancer. Curr Opin Immunol, 8, 643–50
   PubMed Web of Science ®Google Scholar
• Tsuji T, Matsuzaki J, Caballero OL, et al. (2012). Heat shock protein 90-mediated peptide-selective presentation of cytosolic tumor antigen for direct recognition of tumors by CD4(+) T cells. J Immunol, 188, 3851–8
   PubMed Web of Science ®Google Scholar
• Tsuji T, Matsuzaki J, Kelly MP, et al. (2011). Antibody-targeted NY-ESO-1 to mannose receptor or DEC-205 in vitro elicits dual human CD8+ and CD4+ T cell responses with broad antigen specificity. J Immunol, 186, 1218–27
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley YH, et al. (2014). PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature, 515, 568–71
   PubMed Web of Science ®Google Scholar
• Tureci O, Sahin U, Zwick C, et al. (1998). Identification of a meiosis-specific protein as a member of the class of cancer/testis antigens. Proc Natl Acad Sci U S A, 95, 5211–16
   PubMed Web of Science ®Google Scholar
• Vacchelli E, Aranda F, Eggermont A, et al. (2014). Trial watch: Tumor-targeting monoclonal antibodies in cancer therapy. OncoImmunology, 3, e27048
   Google Scholar
• Vacchelli E, Martins I, Eggermont A, et al. (2012). Trial watch: Peptide vaccines in cancer therapy. Oncoimmunology, 1, 1557–76
   PubMed Web of Science ®Google Scholar
• Van den Eynde BJ, Boon T. (1997). Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res, 27, 81–6
   PubMedGoogle Scholar
• van der Bruggen P, Traversari C, Chomez P, et al. (1991). A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science, 254, 1643–7
   PubMed Web of Science ®Google Scholar
• Walter S, Weinschenk T, Stenzl A, et al. (2012). Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med, 18, 1254–61
   PubMed Web of Science ®Google Scholar
• Wang LX, Shu S, Disis ML, Plautz GE. (2007). Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response. Blood, 109, 4865–76
   PubMed Web of Science ®Google Scholar
• Wick DA, Webb JR, Nielsen JS, et al. (2014). Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. Clin Cancer Res, 20, 1125–34
   PubMed Web of Science ®Google Scholar
• Wolfel T, Hauer M, Schneider J, et al. (1995). A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. Science, 269, 1281–4
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MV, et al. (2012). Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res, 72, 917–27
   PubMed Web of Science ®Google Scholar
• Zhang L, Conejo-Garcia JR, Katsaros D, et al. (2003). Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med, 348, 203–13
   PubMed Web of Science ®Google Scholar
• Zsiros E, Tsuji T, Odunsi K. (2015). Adoptive T-cell therapy is a promising salvage approach for advanced or recurrent metastatic cervical cancer. J Clin Oncol, 33, 1521–2
   PubMed Web of Science ®Google Scholar